Navigation Links
PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022
Date:10/24/2013

London (PRWEB) October 24, 2013

PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Being the most populated nation in the world and having a government with ample resources, China could potentially observe astounding AD drug growth during the forecast period. Unfortunately, we do not envision this to occur within the next 10 years due to China’s acceptance of its underdeveloped healthcare infrastructure. The lack of access to healthcare in rural parts of the nation, the limited provision of social services, and limited efforts to maintain adequate public health suggest that there are many areas that require significant changes before the topic of AD can be properly addressed.

Scope

-Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in China from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting China Alzheimer’s Disease market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the cha
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
6. PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022
8. Changes in Epigenetic DNA Functions Reveal How Diabetes Predisposes Individuals to Alzheimer’s Disease
9. Diamond Fitness to Host Senior Dinner Dance to Raise Money for the Alzheimer’s Association
10. Eldercare Expert Judie Rappaport Releases New Report on the Rising Impact of Alzheimer’s Disease on the American Family
11. Feinstein Institute Researcher Organizes LI Alzheimer’s Consortium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... a Viewpoint published today in the Journal of ... researchers call for the implementation of taxes and subsidies ... researchers from the Friedman School of Nutrition Science and ... Hospital write that policies taxing nearly all packaged foods ... meaningful dietary changes and substantially reduce health care costs. ...
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... The use of Xarelto (known generically ... at a rapid pace, even as Xarelto lawsuits ... the U.S., Bernstein Liebhard LLP reports. According to a ... a year of its 2011 launch, patients were just ... blood thinner that has been in use for several ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... In a large population-based study of randomly selected ... impairment (MCI) occurred twice more often in individuals ... strong association was only observed in middle-aged participants ... the association vanished. This study is published in ... The concept of MCI describes an intermediate state ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2
... study may help put to rest fears that pregnancy ... receiving antiretroviral therapy. The study, published in the October ... now available online, revealed that pregnancy may, in fact, ... advent of highly active antiretroviral therapy (HAART), many women ...
... Segal Health Plan Cost,Trend Survey forecasts continued declines in ... medical trends. And, although a growing,number of health plans ... still significantly above general inflation. Key findings,include: ... for point-of-service (POS) medical ...
... District,Court for the District of Massachusetts has granted ... a class of people and entities that,purchased certain ... Health Benefits Fund v. First DataBank, Inc., No.,1:05-CV-11148-PBS ... Medi-Span, No.,07-cv-10988-PBS, concerning how the published price of ...
... of parents feel they play a significant role in ... at the University of Michigan C.S. Mott Childrens Hospital. ... issue of the Journal of Pediatrics, 86 percent of ... their hospitalized childs medical care. Researchers also found that ...
... Medicine (BUSM), Boston University School of Public Health ... Institute (NHLBI), have completed analyses of a genome-wide ... participants from the landmark Framingham Heart Study (FHS). ... potentially affect the risk for cardiovascular disease and ...
... researchers say , , WEDNESDAY, Sept. 19 (HealthDay News) ... knew little or nothing about peripheral arterial disease (PAD), ... legs that boosts heart risk. , "I don,t think ... PAD," said Dr. Timothy Murphy, a professor of diagnostic ...
Cached Medicine News:Health News:Pregnancy may slow -- not accelerate -- progression to AIDS 2Health News:Pregnancy may slow -- not accelerate -- progression to AIDS 3Health News:Segal Survey Predicts Declines in Trends for Fifth Consecutive Year 2Health News:Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals 2Health News:Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals 3Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits 2Health News:Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits 3Health News:Few Americans Know of Leg Artery Danger 2Health News:Few Americans Know of Leg Artery Danger 3
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... , September 2, 2014 Today, ... (NYSE: WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ZTS ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted ...
(Date:9/2/2014)... DUBLIN , Sept. 2, 2014 Actavis ... the U.S. Food and Drug Administration (FDA) has accepted ... an investigational drug for the treatment of diarrhea and ... Irritable Bowel Syndrome (IBS-D).  Actavis, NDA for eluxadoline has ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The ...
Breaking Medicine Technology:Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4
... Australia, Sept. 26 Hospira, Inc. (NYSE: ... injectable pharmaceuticals, today announced that it has received ... biosimilar filgrastim product, Nivestim™. Nivestim ... including the prevention of febrile neutropenia (FN) and ...
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
Cached Medicine Technology:Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 2Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: